Paper · 41318657

RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.

Lin S and 12 others. Cell Death Dis, 2025. Cited by 2 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion. Papers, record 41318657. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41318657

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.; PubMed
Journal: Cell Death Dis; PubMed
Year: 2025; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/41318657/; PubMed
DOI: https://doi.org/10.1038/s41419-025-08259-8; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12827460/; PubMed
The journal: https://conductscience.org/library/journal-index/101524092; PubMed
Citations, by iCite: 2; iCite
Revised in PubMed: 2026-01-25; PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Lin S	Shiqi	https://orcid.org/0000-0002-6467-3365
2	Tang D	Dongyang
3	Lei JH	Josh Haipeng	https://orcid.org/0000-0002-2058-8054
4	Chu X	Xiangpeng
5	Wang L	Lijian	https://orcid.org/0000-0002-2726-9654
6	Miao K	Kai	https://orcid.org/0000-0003-4832-3354
7	Chen P	Ping
8	Zhou J	Jingbo
9	Zhang A	Aiping
10	Li L	Ling

1 to 10 of 13Source PubMed

See all 13 authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Triple Negative Breast Neoplasms	Major topic
Enhancer of Zeste Homolog 2 Protein	Major topic
DNA-Binding Proteins	Major topic
Animals
Humans
Mice
Female
Cell Line, Tumor
Estrogen Receptor alpha
Gene Expression Regulation, Neoplastic

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
82030094	National Natural Science Foundation of China (National Science Foundation of China)			PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	16,778,215	Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.	Cancer Res	2006	https://conductscience.org/library/papers/16778215	PubMed
2	17,496,925	A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation.	Oncogene	2007	https://conductscience.org/library/papers/17496925	PubMed
3	11,585,728	Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.	Cancer Res	2001	https://conductscience.org/library/papers/11585728	PubMed
4	17,975,657	Breast cancer: origins and evolution.	J Clin Invest	2007	https://conductscience.org/library/papers/17975657	PubMed
5	17,529,973	A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer.	Nat Genet	2007	https://conductscience.org/library/papers/17529973	PubMed
6	16,199,517	Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.	Proc Natl Acad Sci U S A	2005	https://conductscience.org/library/papers/16199517	PubMed
7	28,042,497	Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.	Am J Cancer Res	2016	https://conductscience.org/library/papers/28042497	PubMed
8	23,166,150	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.	Ann Oncol	2012	https://conductscience.org/library/papers/23166150	PubMed
9	31,704,972	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.	Nat Commun	2019	https://conductscience.org/library/papers/31704972	PubMed
10	11,709,723	Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.	Oncogene	2001	https://conductscience.org/library/papers/11709723	PubMed

1 to 10 of 61

See all 61 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41318657

GET https://conductscience.org/api/papers/v1/41318657/references?page=2

API reference For AI assistants